Tag: Sanofi
Auvi-Q Takes Center Stage at School Nurse Conference
One example of the changing market dynamics for epinephrine auto-injectors in light of recent developments.
Mylan’s Chairman Was Paid $97.6 Million
Despite 2016 being a year when everything seemed to implode for the marketer of EpiPen.
Sanofi Files Suit Against Mylan for Anti-Competitive EpiPen Strategy
More legal troubles for the embattled marketer of EpiPen.
Auvi-Q Goes On Sale Today with a Bold Pricing and Distribution Structure
Innovation and participation by insurers will be key to the successful reintroduction of the device.
Kaleo Takes a Bold Step as Auvi-Q Returns
The company pledges $0 out-of-pocket expenses for many when the auto-injector is reintroduced February 14. FAQ included in article.
The Reliability of Auvi-Q: An Interview with Eric Edwards
We discuss the changes kaléo is making to the manufacture and quality assurance of Auvi-Q prior to its reintroduction in 2017.
Epinephrine Auto-injectors: Where is the Long Promised Generic?
We were supposed to have a generic alternative last year. What's holding it up and when can we expect it?
Sanofi Abandons Auvi-Q, Allerject
Whether the product will ever be reintroduced remains to be seen.
What ‘Voluntary’ Recall Means and Why You Should Care
As the consumer of a lifesaving medical device, it's important to know what the term actually implies.
Editorial: Regarding the Petition to Bring Auvi-Q Back
We need to know much more about the shortcomings of the device before urging Sanofi to return it to market.
